newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent - Received orphan drug and fast-track designation from the U.S. FDA for lead pipeline candidate, ITIL-168, in melanoma - Expansion of manufacturing cap